Copy
December 2016


InSource partners in global diabetes study
 
InSource is a research partner in a global initiative to reduce the impact of type 2 diabetes (DM2) in urban settings. Funded by the Danish pharmaceutical company Novo Nordisk, Cities Changing Diabetes (CCD) is studying DM2 in seven cities worldwide, including Vancouver, to find ways to improve prevention and care for the disease.  The Vancouver project was launched on World Diabetes Day, November 14th, and recently profiled in a front-page article in the Vancouver Sun.  
 
The CCD initiative is designed to reveal the extent of preventable diabetes and to implement intervention strategies co-designed with local communities using a collective impact systems approach.  Mapping the prevalence of DM2 using existing data, InSource found about 60,000 people in Vancouver live with the disease, representing a prevalence rate of 9.6 per cent. However, only 77 percent of Vancouverites with DM2 have been diagnosed. Using existing databases, further work will reveal how many people in the city diagnosed with DM2 are receiving treatment and achieving optimal outcomes



For more information about InSource, visit our website – www.in-source.ca or contact us at info@in-source.ca.
 
 

Copyright © 2016  |nSource, All rights reserved.

Our mailing address is:
982 Thermal Drive
Coquitlam BC V3J 6S1

Info@InSource.ca










This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
InSource Research Group · 982 Thermal Drive · Coquitlam, BC V3J 6S1 · Canada

Email Marketing Powered by Mailchimp